科研之友
微信
新浪微博
Facebook
分享链接
摘要
<正>Pancreatic ductal adenocarcinoma(PDAC) remains still one of the most lethal tumor entities and will be the second leading cause of cancer-related death within the next ten years for both male and female patients. This frustrating development is mainly explained by an increasing incidence and still limited therapeutical success [ 1, 2 ]. Only about 15%-20% of all patients diagnosed with PDAC qualify for upfront surgery, while in the remaining patients,
